Grundlæggende statistik
| CIK | 1078037 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Remedent, Inc.
SEC Filings (Chronological Order)
Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.
| June 30, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2021 REMEDENT, INC. |
|
| June 30, 2021 |
EXHIBIT 99.1 REMEDENT, INC. FILES FORM 15 TO SUSPEND SEC EXCHANGE ACT REGISTRATION AND APPLIES TO QUALIFY FOR OTC MARKETS ALTERNATIVE REPORTING STANDARD FOR PINK SHEET COMPANIES GHENT, Belgium, June 29, 2021 - Remedent, Inc. (OTC Pink: REMI) (?Remedent? or the ?Company?) announced today the voluntary filing of a Form 15 with the United States Securities and Exchange Commission (the "SEC") to termi |
|
| June 29, 2021 |
15-12G 1 remedentform15v6.htm FORM 15 OMB APPROVAL OMB Number: 3235-0167 Expires: May 31, 2021 Estimated average burden hours per response..... 1.50 United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-15975 REMEDENT, I |
|
| November 16, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2020 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-15975 REMEDENT, |
|
| August 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2020 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-15975 REMEDENT, INC. |
|
| June 30, 2020 |
EX-21.1 2 tm2015463d1ex21-1.htm EXHIBIT 21.1 Exhibit 21.1 List of Subsidiaries of Remedent, Inc. We have the following wholly owned subsidiaries: (1) Remedent N.V., a Belgium corporation (“Remedent NV”); (2) Remedent Professional Holdings, Inc., a California corporation; (3) Remedent Professional, Inc., a California corporation (a subsidiary of Remedent Professional Holdings, Inc.), (4) Glamtech-U |
|
| June 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2020 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-15975 REMEDENT, INC. (Name of small business issuer as specified in it |
|
| February 14, 2020 |
REMI / Remedent, Inc. 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2019 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-15975 REMEDENT, I |
|
| November 14, 2019 |
REMI / Remedent, Inc. 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2019 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-15975 REMEDENT, |
|
| August 14, 2019 |
REMI / Remedent, Inc. 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2019 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-15975 REMEDENT, INC. |
|
| June 28, 2019 |
EX-21.1 2 tv523589ex21-1.htm EXHIBIT 21.1 Exhibit 21.1 List of Subsidiaries of Remedent, Inc. We have the following wholly owned subsidiaries: (1) Remedent N.V., a Belgium corporation (“Remedent NV”); (2) Remedent Professional Holdings, Inc., a California corporation; (3) Remedent Professional, Inc., a California corporation (a subsidiary of Remedent Professional Holdings, Inc.), (4) Glamtech-USA, |
|
| June 28, 2019 |
REMI / Remedent, Inc. 10-K - Annual Report - FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2019 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-15975 REMEDENT, INC. (Name of small business issuer as specified in it |
|
| February 14, 2019 |
REMI / Remedent, Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2018 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-15975 REMEDENT, I |
|
| November 14, 2018 |
REMI / Remedent, Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2018 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-15975 REMEDENT, |
|
| August 14, 2018 |
REMI / Remedent, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2018 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-15975 REMEDENT, INC. |
|
| July 13, 2018 |
REMI / Remedent, Inc. FORM 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2018 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-15975 REMEDENT, INC. (Name of small business issuer as specified in it |
|
| July 13, 2018 |
Exhibit 21.1 List of Subsidiaries of Remedent, Inc. We have the following wholly owned subsidiaries: (1) Remedent N.V., a Belgium corporation (“Remedent NV”); (2) Remedent Professional Holdings, Inc., a California corporation; (3) Remedent Professional, Inc., a California corporation (a subsidiary of Remedent Professional Holdings, Inc.), (4) Glamtech-USA, Inc., a Delaware corporation (“Glamtech”) |
|
| June 27, 2018 |
NT 10-K 1 tv497033nt10-k.htm NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0058 Expires: July 1, 2018 Estimated average burden hours per response . . . . . . . 2.50 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-15975 CUSIP NUMBER (Check one): x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form |
|
| April 12, 2018 |
CORRESP 1 filename1.htm United States Securities and Exchange Commission March 10, 2018 Page 1 of 3 March 10, 2018 VIA EDGAR United States Securities and Exchange Commission Attention: Kevin J. Kuhar, Accounting Branch Chief Office of Electronics and Machinery 100 F Street, N.E. Washington, DC 20549-6010 Re: Remedent, Inc. Form 10-K for the year ended March 31, 2017 Filed July 29, 2017 Form 10-Q f |
|
| February 14, 2018 |
REMI / Remedent, Inc. FORM 10-Q (Quarterly Report) 10-Q 1 tv48499410-q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2017 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commiss |
|
| November 14, 2017 |
REMI / Remedent, Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2017 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-15975 REMEDENT, |
|
| August 14, 2017 |
REMI / Remedent, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2017 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-15975 REMEDENT, INC. |
|
| June 29, 2017 |
List of Subsidiaries of Remedent, Inc. EX-21.1 2 v469300ex21-1.htm EXHIBIT 21.1 Exhibit 21.1 List of Subsidiaries of Remedent, Inc. We have the following wholly owned subsidiaries: (1) Remedent N.V., a Belgium corporation (“Remedent NV”); (2) Remedent Professional Holdings, Inc., a California corporation; (3) Remedent Professional, Inc., a California corporation (a subsidiary of Remedent Professional Holdings, Inc.), (4) Glamtech-USA, |
|
| June 29, 2017 |
REMI / Remedent, Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2017 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-15975 REMEDENT, INC. (Name of small business issuer as specified in it |
|
| February 14, 2017 |
Remedent 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2016 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-15975 REMEDENT, I |
|
| November 14, 2016 |
Remedent FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2016 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-15975 REMEDENT, |
|
| August 15, 2016 |
Remedent FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2016 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-15975 REMEDENT, INC. |
|
| June 29, 2016 |
List of Subsidiaries of Remedent, Inc. EX-21.1 2 v442653ex21-1.htm EXHIBIT 21.1 Exhibit 21.1 List of Subsidiaries of Remedent, Inc. We have the following wholly owned subsidiaries: (1) Remedent N.V., a Belgium corporation (“Remedent NV”); (2) Remedent Professional Holdings, Inc., a California corporation; (3) Remedent Professional, Inc., a California corporation (a subsidiary of Remedent Professional Holdings, Inc.), and (4) Glamtech-U |
|
| June 29, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2016 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-15975 REMEDENT, INC. (Name of small business issuer as specified in it |
|
| April 6, 2016 |
April 6, 2016 VIA EDGAR United States Securities and Exchange Commission Attention: Martin James, Senior Assistant Chief Accountant Office of Electronics and Machinery 100 F Street, N. |
|
| March 16, 2016 |
United States Securities and Exchange Commission March 15, 2016 Page 1 of 4 March 15, 2016 VIA EDGAR United States Securities and Exchange Commission Attention: Martin James, Senior Assistant Chief Accountant Office of Electronics and Machinery 100 F Street, N. |
|
| February 16, 2016 |
REMI / Remedent, Inc. 10-Q - Quarterly Report - FORM 10-Q 10-Q 1 v43082610q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2015 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commissio |
|
| December 2, 2015 |
REMI / Remedent, Inc. / Sternberg Stuart - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 REMEDENT, INC. (Name of Issuer) Common Stock, no par value per share (Title of Class of Securities) 75954T104 (CUSIP Number) December 2, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche |
|
| November 16, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2015 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-15975 REMEDENT, |
|
| August 14, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2015 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-15975 REMEDENT, INC. |
|
| June 29, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2015 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-15975 REMEDENT, INC. (Name of small business issuer as specified in it |
|
| June 29, 2015 |
List of Subsidiaries of Remedent, Inc. Exhibit 21.1 List of Subsidiaries of Remedent, Inc. We have the following wholly owned subsidiaries: (1) Remedent N.V., a Belgium corporation (?Remedent NV?); (2) Remedent Professional Holdings, Inc., a California corporation; (3) Remedent Professional, Inc., a California corporation (a subsidiary of Remedent Professional Holdings, Inc.), and (4) Glamtech-USA, Inc., a Delaware corporation (?Glamte |
|
| February 23, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2014 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-15975 REMEDENT, I |
|
| February 17, 2015 |
REMI / Remedent, Inc. NT 10-Q - - NT 10-Q NT 10-Q 1 v401931nt10q.htm NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0058 Expires: April 30, 2015 Estimated average burden hours per response . . . . . . . 2.50 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-15975 CUSIP NUMBER (Check one): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form |
|
| November 19, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2014 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-15975 REMEDENT, |
|
| November 14, 2014 |
REMI / Remedent, Inc. NT 10-Q - - NT 10-Q NT 10-Q 1 v394386nt10q.htm NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0058 Expires: April 30, 2015 Estimated average burden hours per response . . . . . . . 2.50 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-15975 CUSIP NUMBER (Check one): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form |
|
| August 19, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2014 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-15975 REMEDENT, INC. |
|
| August 14, 2014 |
REMI / Remedent, Inc. NT 10-Q - - NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0058 Expires: April 30, 2015 Estimated average burden hours per response . . . . . . . 2.50 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-15975 CUSIP NUMBER (Check one): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: June 30, 2 |
|
| July 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2014 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-15975 REMEDENT, INC. (Name of small business issuer as specified in it |
|
| July 14, 2014 |
List of Subsidiaries of Remedent, Inc. Exhibit 21.1 List of Subsidiaries of Remedent, Inc. We have the following wholly owned subsidiaries: (1) Remedent N.V., a Belgium corporation (“Remedent NV”); (2) Remedent Professional Holdings, Inc., a California corporation; (3) Remedent Professional, Inc., a California corporation (a subsidiary of Remedent Professional Holdings, Inc.), and (4) Glamtech-USA, Inc., a Delaware corporation (“Glamte |
|
| July 1, 2014 |
REMI / Remedent, Inc. NT 10-K - - NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0058 Expires: July 1, 2014 Estimated average burden hours per response . . . . . . . 2.50 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-15975 CUSIP NUMBER (Check one): x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: March 31, 20 |
|
| February 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2013 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-15975 REMEDENT, I |
|
| December 2, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Amendment No. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Amendment No. 2 (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2013 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-15975 |
|
| December 2, 2013 |
December 2, 2013 VIA FAX & EDGAR – fax # = (703)813.6985 - number of pages = 2 United States Securities and Exchange Commission Division of Corporation Finance Washington, D.C. 20549 Attention: Martin James, Senior Assistant Staff Accountant RE: Remedent, Inc. Form 10-K for the Fiscal Year Ended March 31, 2013 Filed July 15, 2013 Amendment No. 1 to Form 10-Q for the Quarterly Period Ended June 30, |
|
| November 19, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2013 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-15975 REMEDENT, |
|
| November 14, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Amendment No. 1 (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2013 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-15975 |
|
| November 14, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response . . . . . . . 2.50 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-15975 CUSIP NUMBER (Check one): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: September |
|
| October 30, 2013 |
October 30, 2013 VIA FAX & EDGAR United States Securities and Exchange Commission Division of Corporation Finance Washington, D. |
|
| October 29, 2013 |
October 22, 2013 VIA EDGAR AND FAX United States Securities and Exchange Commission Division of Corporation Finance Washington, D. |
|
| October 16, 2013 |
Changes in Registrant's Certifying Accountant - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2013 REMEDENT, INC. (Exact name of registrant as specified in its charter) Nevada 001-15975 86-0837251 (State or other jurisdiction (Commission (I.R.S. Employer of incorpo |
|
| October 16, 2013 |
EX-1.1 2 v357456ex1-1.htm EX-1.1 Exhibit 1.1 October 14, 2013 Securities and Exchange Commission Office of the Chief Accountant PCAOB Letter file 100 F Street, N.E. Washington, D.C. 20549 Re: REMEDENT, INC. File No. 001-15975 Dear Sir or Madam: We have read Item 4.01, subsection (a) of the Form 8-K filing of Remedent, Inc. dated October 14, 2013. We agree with the statements concerning our Firm co |
|
| August 14, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2013 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-15975 REMEDENT, INC. |
|
| August 1, 2013 |
REMI / Remedent, Inc. / Sternberg Stuart - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 REMEDENT, INC. (Name of Issuer) Common Stock, no par value per share (Title of Class of Securities) 75954T104 (CUSIP Number) July 24, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| July 15, 2013 |
List of Subsidiaries of Remedent, Inc. Exhibit 21.1 List of Subsidiaries of Remedent, Inc. We have the following wholly owned subsidiaries: (1) Remedent N.V., a Belgium corporation (?Remedent NV?); (2) Remedent Professional Holdings, Inc., a California corporation; (3) Remedent Professional, Inc., a California corporation (a subsidiary of Remedent Professional Holdings, Inc.), and (4) Glamtech-USA, Inc., a Delaware corporation (?Glamte |
|
| July 15, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2013 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-15975 REMEDENT, INC. (Name of small business issuer as specified in it |
|
| June 28, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0058 Expires: July 1, 2013 Estimated average burden hours per response . . . . . . . 2.50 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-15975 CUSIP NUMBER (Check one): x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: March 31, 20 |
|
| February 14, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2012 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-15975 REMEDENT, I |
|
| February 13, 2013 |
REMI / Remedent, Inc. / GRUBER & MCBAINE CAPITAL MANAGEMENT LLC Passive Investment OMB APPROVAL OMB Number: 3235-0145 Expires: January 31, 2014 Estimated average burden hours per response. |
|
| November 14, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2012 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-15975 REMEDENT, |
|
| August 14, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2012 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-15975 REMEDENT, INC. |
|
| August 8, 2012 |
8-K 1 v3206808k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2012 REMEDENT, INC. (Exact name of registrant as specified in its charter) Nevada (State or Other Jurisdiction of Incorporation) 001-15975 (Comm |
|
| July 17, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2012 REMEDENT, INC. (Exact name of Registrant as Specified in its Charter) Nevada (State or Other Jurisdiction of Incorporation) 001-15975 (Commission File Number) 86-0837251 |
|
| July 16, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2012 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-15975 REMEDENT, INC. (Name of small business issuer as specified in it |
|
| July 16, 2012 |
EXECUTION VERSION DISTRIBUTION, LICENSE AND MANUFACTURING AGREEMENT FOR GLAMSMILE VENEER PRODUCTS by and among REMEDENT, INC. |
|
| July 16, 2012 |
Termination and License Agreement dated March 27, 2012 (7) EX-10.5 3 v317610ex10-5.htm EXHIBIT 10.5 FINAL TERMINATION AND LICENSE AGREEMENT THIS TERMINATION AND LICENSE AGREEMENT (this “Agreement”) is entered into by and among Remedent, Inc., a Nevada corporation (“Remedent Nevada”), Remedent N.V., a Belgian corporation (“Remedent Belgium”, and together with Remedent Nevada, “Remedent”), and Den-Mat Holdings, LLC, a Delaware limited liability company (“De |
|
| July 16, 2012 |
List of Subsidiaries of Remedent, Inc. EX-21.1 4 v317610ex21-1.htm EXHIBIT 21.1 Exhibit 21.1 List of Subsidiaries of Remedent, Inc. We have the following wholly owned subsidiaries: (1) Remedent N.V., a Belgium corporation (“Remedent NV”); (2) Remedent Professional Holdings, Inc., a California corporation; (3) Remedent Professional, Inc., a California corporation (a subsidiary of Remedent Professional Holdings, Inc.), and (4) Glamtech-U |
|
| June 29, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0058 Expires: June 30, 2012 Estimated average burden hours per response . . . . . . . 2.50 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-15975 CUSIP NUMBER (Check one): x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: March 31, 2 |
|
| February 21, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2011 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-15975 REMEDENT, I |
|
| February 17, 2012 |
REMI / Remedent, Inc. / GRUBER & MCBAINE CAPITAL MANAGEMENT LLC Passive Investment OMB APPROVAL OMB Number: 3235-0145 Expires: January 31, 2013 Estimated average burden hours per response. |
|
| February 14, 2012 |
Remedent Announces Strategic Investment by IDG-Accel EX-99.1 2 v302342ex99-1.htm EXHIBIT 99.1 Remedent Announces Strategic Investment by IDG-Accel http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=850540&ProfileId=051205&sourceType=1 GHENT, BELGIUM - (Marketwire) - 02/13/12 - Remedent, Inc. ("Remedent" or the "Company") (OTCBB: REMI), an international company specializing in research, development, and the manufacturing of oral ca |
|
| February 14, 2012 |
Remedent Announces Shareholder Conference Call to Be Held on Wednesday, February 15, 2012 EX-99.2 3 v302342ex99-2.htm EXHIBIT 99.2 Remedent Announces Shareholder Conference Call to Be Held on Wednesday, February 15, 2012 http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=850874&ProfileId=051205&sourceType=1 GHENT, BELGIUM - (Marketwire) - 02/13/12 - Remedent, Inc. ("Remedent" or the "Company") (OTCBB: REMI), an international company specializing in research, developm |
|
| February 14, 2012 |
8-K 1 v3023428k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2012 REMEDENT, INC. (Exact name of Registrant as Specified in its Charter) Nevada (State or Other Jurisdiction of Incorporation) 001-15975 (C |
|
| February 14, 2012 |
EX-99.3 4 v302342ex99-3.htm EXHIBIT 99.3 Group REMI Stockholder Update Dear Sir, As an existing shareholder, I would like to provide you with an update on the recent developments made by our new client Remedent, Inc. (OTCBB: REMI). Since we met Remedent’s CEO Guy De Vreese and David Lok, CEO of GlamSmile Dental Technologies Ltd. (“Glamsmile Asia”), last summer, Remedent has made tremendous strides |
|
| February 14, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0058 Expires: May 31, 2012 Estimated average burden hours per response . . .. . . 2.50 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER CUSIP NUMBER (Check one): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: December 31, 2011 ¨ Trans |
|
| February 14, 2012 |
REMI / Remedent, Inc. / GRUBER & MCBAINE CAPITAL MANAGEMENT LLC Passive Investment OMB APPROVAL OMB Number: 3235-0145 Expires: January 31, 2013 Estimated average burden hours per response. |
|
| February 2, 2012 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2012 REMEDENT, INC. (Exact name of Registrant as Specified in its Charter) Nevada (State or Other Jurisdiction of Incorporation) 001-15975 (Commission File Number) 86-0837 |
|
| November 21, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2011 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-15975 REMEDENT, |
|
| November 14, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0058 Expires: May 31, 2012 Estimated average burden hours per response . . . . . . . 2.50 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-15975 CUSIP NUMBER (Check one): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: September 30 |
|
| August 16, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2011 REMEDENT, INC. (Exact name of Registrant as Specified in its Charter) Nevada (State or Other Jurisdiction of Incorporation) 001-15975 (Commission File Number) 86-08372 |
|
| August 16, 2011 |
REMEDENT REPORTS FIRST QUARTER RESULTS AND TO HOST CONFERENCE CALL ON AUGUST 18, 2011 EX-99.1 2 v232277ex99-1.htm EXHIBIT 99.1 REMEDENT REPORTS FIRST QUARTER RESULTS AND TO HOST CONFERENCE CALL ON AUGUST 18, 2011 Ghent, Belgium-(Marketwire-8/15/11)-Remedent, Inc., (OTCBB:REMI-News), An international company specializing in research, development, and manufacturing of oral care and cosmetic dentistry products, reported results for the first quarter ended June 30, 2011 (in US Dollars) |
|
| August 15, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2011 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-15975 REMEDENT, INC. |
|
| July 15, 2011 |
Exhibit 99.1 Remedent Reports Fourth Quarter and Year End Results and to Host a Conference Call at 10 AM EST, Tuesday, July 19, 2011 Gent, Belgium?(marketwire-07/15/2011)-Remedent, Inc. (OTC.BB:REMI-News), an international company specializing in research, development, and manufacturing of oral care and cosmetic dentistry products, reported results for the fourth quarter and for the year ended Mar |
|
| July 15, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2011 REMEDENT, INC. (Exact name of Registrant as Specified in its Charter) Nevada (State or Other Jurisdiction of Incorporation) 001-15975 (Commission File Number) 86-0837251 |
|
| July 14, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2011 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-15975 REMEDENT, INC. (Name of small business issuer as specified in it |
|
| July 14, 2011 |
List of Subsidiaries of Remedent, Inc. Exhibit 21.1 List of Subsidiaries of Remedent, Inc. We have the following wholly owned subsidiaries: (1) Remedent N.V., a Belgium corporation (“Remedent NV”); (2) Remedent Professional Holdings, Inc., a California corporation; (3) Remedent Professional, Inc., a California corporation (a subsidiary of Remedent Professional Holdings, Inc.), and (4) Glamtech-USA, Inc., a Delaware corporation (“Glamte |
|
| June 29, 2011 |
UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: May 31, 2012 Estimated average burden hours per response . . . . . . . 2.50 FORM 12b-25 SEC FILE NUMBER 001-15975 NOTIFICATION OF LATE FILING CUSIP NUMBER (Check one):x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: March 31, 201 |
|
| June 24, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2010 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-15975 REMEDENT, INC. (Name of small business issue |
|
| June 9, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2011 REMEDENT, INC. (Exact name of Registrant as Specified in its Charter) Nevada (State or Other Jurisdiction of Incorporation) 001-15975 (Commission File Number) 86-0837251 |
|
| June 2, 2011 |
Sincerely, /s/ Stephen Ross Stephen Ross, Chief Financial Officer June 2, 2011 VIA EDGAR AND FAX United States Securities and Exchange Commission Attention: Kevin L. |
|
| May 6, 2011 |
May 6, 2011 VIA EDGAR AND FAX United States Securities and Exchange Commission Attention: Kevin L. |
|
| March 30, 2011 |
8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2011 REMEDENT, INC. (Exact name of Registrant as Specified in its Charter) Nevada (State or Other Jurisdiction of Incorporation) 001-15975 (Commission File |
|
| March 30, 2011 |
EX-10.2 3 ex10-2.htm EXHIBIT 10.2 SECURITY AGREEMENT THIS SECURITY AGREEMENT, dated as of March 25, 2011 (this “Agreement”), is by and between Remedent, Inc., a Nevada corporation ( the “Debtor”) and Abraham Taff (referred to as “Secured Party”). RECITALS WHEREAS, Debtor and Secured Party have entered into that certain Loan Agreement dated as of the date hereof (as amended, supplemented or modifie |
|
| March 30, 2011 |
EX-10.1 2 ex10-1.htm EXHIBIT 10.1 LOAN AGREEMENT This LOAN AGREEMENT (this "Agreement") is made as of March 25, 2011, by and among Remedent, Inc., a Nevada corporation (the "Company"), and Abraham Taff (the "Lender"). WHEREAS, subject to the terms and conditions set forth in this Agreement the Company desires to borrow from the Lender, and the Lender desires to lend to the Company an aggregate amo |
|
| March 30, 2011 |
SECURED PROMISSORY NOTE DUE DECEMBER 31, 2011 EX-10.3 4 ex10-3.htm EXHIBIT 10.3 $500,000 March 25, 2011 SECURED PROMISSORY NOTE DUE DECEMBER 31, 2011 FOR VALUE RECEIVED, REMEDENT, INC., a Nevada corporation (the “Company”) promises to pay to Abraham Taff, or its registered assigns (the “Holder”), or shall have paid pursuant to the terms hereunder, the total sum of $500,000, which represents all interest, fees, charges, damages, obligations, a |
|
| March 25, 2011 |
March 25, 2011 VIA EDGAR AND FAX United States Securities and Exchange Commission Attention: Kevin I. |
|
| February 28, 2011 |
Glamsmile Opens Shanghai Studio on February 21, 2011 EX-99 2 ex99-1.htm Exhibit 99.1 Glamsmile Opens Shanghai Studio on February 21, 2011 Press Release Source: Remedent, Inc. On Wednesday February 23, 2011, 4:46 pm EST DEURLE, BELGIUM-(Marketwire - 02/23/11) - Remedent, Inc. (OTC.BB:REMI - News), an international company specializing in research, development, and the manufacturing of oral and cosmetic dentistry products, opened its largest four chai |
|
| February 28, 2011 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2011 REMEDENT, INC. (Exact name of registrant as specified in its charter) Nevada (State or Other Jurisdiction of Incorporation) 001-15975 (Commission File Number) 86-083 |
|
| February 14, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2010 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-15975 REMEDENT, I |
|
| January 24, 2011 |
OMB APPROVAL OMB Number: 3235-0145 Expires: January 31, 2011 Estimated average burden hours per response. |
|
| November 15, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ¨ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2010 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-15975 REMEDENT, |
|
| September 23, 2010 |
Exhibit 10.34 AMENDMENT NO. 2 TO AMENDED AND RESTATED DISTRIBUTION, LICENSE AND MANUFACTURING AGREEMENT (GLAMSMILE) THIS AMENDMENT NO. 2 TO AMENDED AND RESTATED DISTRIBUTION, LICENSE AND MANUFACTURING AGREEMENT (this ?Agreement?) is made as of February 16, 2010 (the ?Amendment No. 2 Effective Date?) by and among Remedent, Inc., a Nevada corporation (?Remedent Nevada?), Remedent N.V., a Belgian cor |
|
| September 23, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM 10-K/A þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2010 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-15975 REMEDENT, INC. (Name of small business issu |
|
| September 23, 2010 |
AMENDMENT NO. 1 TO FIRST FIT-CROWN DISTRIBUTION AND LICENSE AGREEMENT EX-10.33 2 v197200ex10-33.htm EXHIBIT 10.33 AMENDMENT NO. 1 TO FIRST FIT-CROWN DISTRIBUTION AND LICENSE AGREEMENT THIS AMENDMENT NO. 1 TO FIRST FIT-CROWN DISTRIBUTION AND LICENSE AGREEMENT (this “Agreement”) is made as of February 16, 2010 (the “Amendment No. 1 Effective Date”) by and among Remedent, Inc., a Nevada corporation (“Remedent Nevada”), Remedent N.V., a Belgian corporation (“Remedent Be |
|
| August 16, 2010 |
EXHIBIT 99.1 FOR IMMEDIATE RELEASE Remedent Reports Profits In First Quarter Remedent to Host a Conference Call to Discuss Results at 11 AM EST, Wednesday, August 18, 2010 Deurle, Belgium-(Marketwire 8/16/2010) Remedent, Inc. (OTCBB:REMI.OB), an international company specializing in research, development, and manufacturing of oral care and cosmetic dentistry products, reported results for the firs |
|
| August 16, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2010 REMEDENT, INC. (Exact name of registrant as specified in its charter) Nevada (State or Other Jurisdiction of Incorporation) 001-15975 (Commission File Number) 86-08372 |
|
| August 16, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2010 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-15975 REMEDENT, INC. |
|
| July 15, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2010 REMEDENT, INC. (Exact name of registrant as specified in its charter) Nevada (State or Other Jurisdiction of Incorporation) 001-15975 (Commission File Number) 86-0837251 |
|
| July 15, 2010 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Remedent Reports Fourth Quarter and Year End Results and Remedent to Host a Conference Call at 11:00 A.M. EST, Tuesday, July 20, 2010. Duerle, Belgium-(Marketwire 7/15/2010) Remedent, Inc. (OTCBB:REMI.OB), an international company specializing in research, development, and manufacturing of oral care and cosmetic dentistry products, reported results for the final |
|
| July 13, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K R ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2010 £ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-15975 REMEDENT, INC. (Name of small business issuer as specified in it |
|
| July 13, 2010 |
Exhibit 10.34 [***] Represents material information which has been redacted and filed separately with the Commission pursuant to a request for confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. AMENDMENT NO. 2 TO AMENDED AND RESTATED DISTRIBUTION, LICENSE AND MANUFACTURING AGREEMENT (GLAMSMILE) THIS AMENDMENT NO. 2 TO AMENDED AND RESTATED DISTRIBUTION |
|
| July 13, 2010 |
AMENDMENT NO. 1 TO FIRST FIT-CROWN DISTRIBUTION AND LICENSE AGREEMENT EXHIBIT 10.33 [***] Represents material information which has been redacted and filed separately with the Commission pursuant to a request for confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. AMENDMENT NO. 1 TO FIRST FIT-CROWN DISTRIBUTION AND LICENSE AGREEMENT THIS AMENDMENT NO. 1 TO FIRST FIT-CROWN DISTRIBUTION AND LICENSE AGREEMENT (this ?Agreeme |
|
| June 28, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0058 Expires: May 31, 2012 Estimated average burden hours per response . . . . . . . 2.50 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-15975 CUSIP NUMBER (Check one): x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: March 31, 20 |
|
| June 1, 2010 |
Veneer Sales Increase Sharply as Remedent Announces Opening of New Super Spa in Taipei, Taiwan Exhibit 99.1 Veneer Sales Increase Sharply as Remedent Announces Opening of New Super Spa in Taipei, Taiwan DEURLE, BELGIUM-(Marketwire - 06/01/10) - Remedent, Inc. (OTC.BB:REMI - News), an international company specializing in research, development, and manufacturing of oral care and cosmetic dentistry products, announced today that its April sales from its Beijing Spa increased by 5 times the sa |
|
| June 1, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2010 REMEDENT, INC. (Exact name of registrant as specified in its charter) Nevada (State or Other Jurisdiction of Incorporation) 001-15975 (Commission File Number) 86-0837251 |
|
| April 16, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2010 REMEDENT, INC. (Exact name of registrant as specified in its charter) Nevada (State or Other Jurisdiction of Incorporation) 001-15975 (Commission File Number) 86-083725 |
|
| April 16, 2010 |
EX-99 2 ex99-1.htm Exhibit 99.1 Veneer Sales Increase As Remedent Announces Inclusion of Chinese Operations in Consolidated Financial Statements for the year and quarter ended March 31, 2010 Remedent’s Expansion in Asian Market Continues With the Opening of Dental Spas in Hong Kong and Taiwan DEURLE, BELGIUM-(Marketwire - 04/15/10) - Remedent, Inc. (OTC.BB:REMI - News), an international company sp |
|
| March 29, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2010 REMEDENT, INC. (Exact name of Registrant as Specified in its Charter) Nevada (State or Other Jurisdiction of Incorporation) 001-15975 (Commission File Number) 86-083725 |
|
| March 29, 2010 |
EXHIBIT 99.1 FOR IMMEDIATE RELEASE REMEDENT ANNOUNCES THE SALE OF ITS FIRST FIT INTELLECTUAL PROPERTY FOR $2.85 MILLION IN CASH, PLUS ROYALTY PAYMENTS ON LUMINEER VENEERS AND FIRST FIT PRODUCTS SOLD BY DEN-MAT DEURLE, BELGIUM— March 29, 2010 — Remedent, Inc. (OTCBB: REMI), an international company specializing in the research, development, and manufacturing of oral care and cosmetic dentistry prod |
|
| March 4, 2010 |
Supplement No. 3 Dated May 14, 2009 Prospectus Supplement No. 3 to Prospectus dated May 14, 2009 Filed Pursuant to Rule 424(b)(3) Registration No. 333-144745 Supplement No. 3 To Prospectus Dated May 14, 2009 This Prospectus Supplement No. 3 supplements our combined Prospectus dated May 14, 2009 as supplemented by that certain Prospectus Supplement No.1 as filed with the Securities and Exchange Commission (“SEC”) on September 2, 2009 |
|
| February 17, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): Ferbuary 17, 2010 REMEDENT, INC. (Exact name of registrant as specified in its charter) Nevada (State or Other Jurisdiction of Incorporation) 001-15975 (Commission File Number) 86-083 |
|
| February 17, 2010 |
Exhibit 99.1 Remedent Reports Fiscal Third Quarter 2010 Results and Remedent to Host a Conference Call at 11:00 am EST, Thursday, February 18, 2010 DEURLE, BELGIUM - February 17, 2010, Remedent, Inc. (OTCBB:REMI - News), an international company specializing in the research, development, and manufacturing of oral care and cosmetic dentistry products, reported results for the fiscal third quarter e |
|
| February 16, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2009 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-15975 REMEDENT, I |
|
| February 2, 2010 |
OMB APPROVAL OMB Number: 3235-0145 Expires: January 31, 2010 Estimated average burden hours per response. |
|
| November 27, 2009 |
Supplement No. 2 Dated May 14, 2009 Prospectus Supplement No. 2 to Prospectus dated May 14, 2009 Filed Pursuant to Rule 424(b)(3) Registration No. 333-144745 Supplement No. 2 To Prospectus Dated May 14, 2009 This Prospectus Supplement No. 2 supplements our combined Prospectus dated May 14, 2009 as supplemented by that certain Prospectus Supplement No.1 as filed with the Securities and Exchange Commission (?SEC?) on September 2, 2009 |
|
| November 17, 2009 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Company Contacts: Investor Relations: Stephen Ross Ron Both Chief Financial Officer Managing Director Remedent, Inc. Liolios Group, Inc. Tel 310-922-5685 Tel 949-574-3860 [email protected] [email protected] Remedent Reports Fiscal Second Quarter 2010 Results Remedent to Reveal New Corporate Website on November 19 and Host a Conference Call at 11:00 a.m. ET DEU |
|
| November 17, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2009 REMEDENT, INC. (Exact name of registrant as specified in its charter) Nevada 001-15975 86-0837251 (State or Other Jurisdiction of (Commission File Number) (IRS Emplo |
|
| November 16, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2009 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-15975 REMEDENT, |
|
| September 2, 2009 |
Supplement No. 1 Dated May 14, 2009 Prospectus Supplement No. 1 to Prospectus dated May 14, 2009 Filed Pursuant to Rule 424(b)(3) Registration No. 333-144745 Supplement No. 1 To Prospectus Dated May 14, 2009 This Prospectus Supplement No. 1 supplements our combined Prospectus dated May 14, 2009 filed with the Securities and Exchange Commission (“SEC”), and includes our Annual Report on Form 10-K for the fiscal year ended March 31, 2 |
|
| September 1, 2009 |
PROSPECTUS 11,808,032 Shares REMEDENT, INC. Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-144745 PROSPECTUS 11,808,032 Shares REMEDENT, INC. Common Stock This combined Prospectus relates to the sale or other disposition of 4,032,287 shares of common stock, $.001 par value, by the Selling Security Holders listed under ?Selling Security Holders? starting on page 15 or their transferees. This Prospectus also covers the sale or other di |
|
| August 17, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2009 REMEDENT, INC. (Exact name of Registrant as Specified in its Charter) Nevada (State or Other Jurisdiction of Incorporation) 001-15975 (Commission File Number) 86-08372 |
|
| August 17, 2009 |
[remainder of page intentionally left blank; signature page follows] Exhibit 10.1 [***] Represents material information which has been redacted and filed separately with the Commission pursuant to a request for confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. AMENDMENT NO. 1 TO AMENDED AND RESTATED DISTRIBUTION, LICENSE AND MANUFACTURING AGREEMENT THIS AMENDMENT NO. 1 TO AMENDED AND RESTATED DISTRIBUTION, LICENSE AND |
|
| August 17, 2009 |
EX-99 3 ex99-1.htm Exhibit 99.1 FOR IMMEDIATE RELEASE Company Contacts: Investor Relations: Stephen Ross Ron Both Chief Financial Officer Managing Director Remedent, Inc. Liolios Group, Inc. Tel (310) 922-5685 Tel (949) 574-3860 [email protected] [email protected] Remedent Introduces GlamStrip, a Revolutionary New Device for Applying GlamSmile Dental Veneers Den-Mat Holdings Expands Distributio |
|
| August 14, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2009 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-15975 REMEDENT, INC. |
|
| August 14, 2009 |
Remedent Sets Fiscal First Quarter 2010 Conference Call for Friday, August 14 at 9:00 a.m. ET Exhibit 99.2 Remedent Sets Fiscal First Quarter 2010 Conference Call for Friday, August 14 at 9:00 a.m. ET DEURLE, Belgium and LOS ANGELES, Calif. ? August 6, 2009 ? Remedent, Inc. (OTCBB: REMI), an international company specializing in the research, development, and manufacturing of oral care and cosmetic dentistry products, will hold a conference call on Friday, August 14, 2009 at 9:00 a.m. East |
|
| August 14, 2009 |
Remedent Reports Fiscal First Quarter 2010 Results Exhibit 99.1 FOR IMMEDIATE RELEASE Company Contacts: Investor Relations: Stephen Ross Ron Both Chief Financial Officer Managing Director Remedent, Inc. Liolios Group, Inc. Tel 310-922-5685 Tel 949-574-3860 [email protected] [email protected] Remedent Reports Fiscal First Quarter 2010 Results DEURLE, BELGIUM and LOS ANGELES, CA ? August 14, 2009 ? Remedent, Inc. (OTCBB: REMI), an international c |
|
| June 29, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2009 REMEDENT, INC. (Exact name of registrant as specified in its charter) Nevada (State or Other Jurisdiction of Incorporation) 001-15975 (Commission File Number) 86-0837251 |
|
| June 29, 2009 |
EXHIBIT 99.2 Remedent Sets Fiscal Fourth Quarter and Year End 2009 Conference Call for Wednesday, July 1 at 11:00 a.m. ET DEURLE, Belgium and LOS ANGELES, Calif. ? June 23, 2009 ? Remedent, Inc. (OTCBB: REMI), an international company specializing in the research, development, and manufacturing of oral care and cosmetic dentistry products, will hold a conference call on Wednesday, July 1, 2009 at |
|
| June 29, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K R ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2009 £ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-15975 REMEDENT, INC. (Name of small business issuer as specified in it |
|
| June 29, 2009 |
EXHIBIT 10.34 [***] Represents material information which has been redacted and filed separately with the Commission pursuant to a request for confidential treatment pursuant to Rule 24b-2 of the Securities Exvhange Act of 1934, as amended. FIRST FIT-CROWN DISTRIBUTION AND LICENSE AGREEMENT by and among REMEDENT, INC., REMEDENT, N.V., and DEN-MAT HOLDINGS, LLC Dated as of June 3, 2009 TABLE OF CON |
|
| June 29, 2009 |
EXHIBIT 10.35 [***] Represents material information which has been redacted and filed separately with the Commission pursuant to a request for confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. AMENDED AND RESTATED DISTRIBUTION, LICENSE AND MANUFACTURING AGREEMENT by and among REMEDENT, INC., REMEDENT, N.V., and DEN-MAT HOLDINGS, LLC Dated as of June |
|
| June 29, 2009 |
EXHIBIT 99.1 FOR IMMEDIATE RELEASE Company Contacts: Investor Relations: Stephen Ross Ron Both Chief Financial Officer Managing Director Remedent, Inc. Liolios Group, Inc. Tel 310-922-5685 Tel (949) 574-3860 [email protected] [email protected] Remedent Reports Fiscal Fourth Quarter and Record Fiscal 2009 Results Record Annual Net Sales of $14.6 Million, Up 96% Year-over-Year, Driven by 564% Inc |
|
| June 9, 2009 |
FOR IMMEDIATE RELEASE Remedent Company Contacts: Remedent Investor Relations: Den-Mat Contact Stephen Ross Ron Both Mike Beyer Chief Financial Officer Managing Director Sam Brown Inc. |
|
| June 9, 2009 |
EX-99 2 ex99-1.htm FOR IMMEDIATE RELEASE Company Contacts: Investor Relations: Stephen Ross Ron Both Scott Liolios Chief Financial Officer Managing Director Remedent, Inc. Liolios Group, Inc. Tel 310-922-5685 Tel (949) 574-3860 [email protected] [email protected] Remedent Introduces FirstFit™, a Revolutionary System for Creation and Placement of Dental Bridges & Crowns FirstFit Computer-Aided P |
|
| June 9, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2009 REMEDENT, INC. (Exact name of Registrant as Specified in its Charter) Nevada (State or Other Jurisdiction of Incorporation) 001-15975 (Commission File Number) 86-0837251 |
|
| May 11, 2009 |
May 11, 2009 Via Facsimile, Original to Follow by U.S. Mail Scott E. Bartel Direct Dial: (916) 930-2513 E-mail: [email protected] May 11, 2009 Via Facsimile, Original to Follow by U.S. Mail Russell Mancuso Branch Chief Securities and Exchange Commission 100 F Street, N.E. Mail Stop 3030 Washington, DC 20549 Re: Remedent, Inc. Post-Effective Amendment No. 1 to Form SB-2 on Form S-1 Filed April 22, 2009 File No. 333-144745 Dear Mr. Mancuso: We repre |
|
| May 11, 2009 |
As filed with the Securities and Exchange Commission on ____________ 2009 As filed with the Securities and Exchange Commission on 2009 Registration No. 333-144745 U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 2 TO FORM SB-2 ON FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 REMEDENT, INC. (Name of small business issuer in its charter) Nevada 3843 86-0837251 (State or jurisdiction of (Primary Standard Industr |
|
| April 22, 2009 |
As filed with the Securities and Exchange Commission on ____________ 2009 As filed with the Securities and Exchange Commission on 2009 Registration No. 333-144745 U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM SB-2 ON FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 REMEDENT, INC. (Name of small business issuer in its charter) Nevada 3843 86-0837251 (State or jurisdiction of (Primary Standard Industr |
|
| April 22, 2009 |
List of Subsidiaries of Remedent, Inc. Exhibit 21 List of Subsidiaries of Remedent, Inc. We have the following wholly owned subsidiaries: (1) Remedent N.V., a Belgium corporation (?Remedent NV?); (2) Remedent Professional Holdings, Inc., a California corporation; (3) Remedent Professional, Inc., a California corporation (a subsidiary of Remedent Professional Holdings, Inc.), and (4) Glamtech-USA, Inc., a Delaware corporation (?Glamtech |
|
| February 23, 2009 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2008 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001 |
|
| February 23, 2009 |
Remedent Sets Third Fiscal Quarter 2009 Conference Call for Tuesday, February 24 at 11:00 a.m. ET EX-99 4 ex99-2.htm Exhibit 99.2 Remedent Sets Third Fiscal Quarter 2009 Conference Call for Tuesday, February 24 at 11:00 a.m. ET DEURLE, Belgium and LOS ANGELES, Calif. - February 18, 2009 - Remedent, Inc. (OTCBB: REMI), an international company specializing in the research, development, and manufacturing of oral care and cosmetic dentistry products, will hold a conference call on Tuesday, Februa |
|
| February 23, 2009 |
8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2009 REMEDENT, INC. (Exact name of registrant as specified in its charter) Nevada (State or Other Jurisdiction of Incorporation) 001-15975 (Commission F |
|
| February 23, 2009 |
EX-99 2 ex99-1.htm Exhibit 99.1 FOR IMMEDIATE RELEASE Company Contacts: Investor Relations: Stephen Ross Ron Both Scott Liolios Chief Financial Officer Managing Director Remedent, Inc. Liolios Group, Inc. Tel 310-922-5685 Tel (949) 574-3860 [email protected] [email protected] Remedent Reports Record Fiscal Third Quarter 2009 Results Record Net Sales of $4.8 Million, Up 127% Over Same Year-Ago P |
|
| February 13, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0058 Expires: April 30, 2009 Estimated average burden hours per response . . . . . . . 2.50 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-15975 CUSIP NUMBER (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: December 3 |
|
| February 3, 2009 |
OMB APPROVAL OMB Number: 3235-0145 Expires: January 31, 2009 Estimated average burden hours per response. |
|
| December 23, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2008 REMEDENT, INC. (Exact name of registrant as specified in its charter) Nevada (State or Other Jurisdiction of Incorporation) 001-15975 (Commission File Number) 86-083 |
|
| December 16, 2008 |
EXECUTION COPY CONTRIBUTION AGREEMENT THIS CONTRIBUTION AGREEMENT (this “Agreement”) is made and entered into by and between Remedent, Inc. |
|
| December 16, 2008 |
EX-10 6 ex10-5.htm INVESTMENT AND SHAREHOLDERS’ AGREEMENT between REMEDENT OTC B.V. CONCORDIA FUND B.V. REMEDENT, INC. ROBIN LIST SYLPHAR HOLDING B.V. and THE EXISTING OTC SUBSIDIARIES (as defined herein) in connection with the investment by Concordia Fund in the OTC business of Remedent 11 December 2008 1 INDEX 1 Interpretation 4 2 Acquisition of Shares and Call Option 5 3 Representations and War |
|
| December 16, 2008 |
EX-10 3 ex10-2.htm EXECUTION COPY Share Purchase Agreement Dated December 10, 2008 Between REMEDENT, INC., a public company incorporated under the laws of Nevada, with its registered offices at Xavier de Cocklaan 42, 9831 Deurle, Belgium, and registered with the company registrar under number C2807329 (“Remedent”); represented by Mr. Robin List, as President, and Mr Guy De Vreese as Chairman of it |
|
| December 16, 2008 |
EX-10 4 ex10-3.htm 1 YC/2008.000939.01 Step 7 CONTRIBUTION OF SHARES On the tenth day of December two thousand eight appeared before me, Michael Johannes Josephus van Tienen, civil law notary Amsterdam: Ms Yee Man Chung, with office address at 1069 DA Amsterdam, Wolbrantskerkweg 40, born at Haarlem on the thirteenth day of April nineteen hundred eighty-two, in this respect acting as duly authorise |
|
| December 16, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2008 REMEDENT, INC. (Exact name of registrant as specified in its charter) Nevada (State or Other Jurisdiction of Incorporation) 001-15975 (Commission File Number) 86-083 |
|
| December 16, 2008 |
EX-10 5 ex10-4.htm EXECUTION COPY Share Purchase Agreement Dated December 10, 2008 Between Mr. Robin List, born on March 28, 1971 in Zaandam, The Netherlands and living in Belgium, Boerestraat 13, 9850-Hansbeke, hereinafter referred to as “Robin List” or the “Purchaser”, on one hand and REMEDENT, INC., a public company incorporated under the laws of Nevada, with its registered offices at Xavier de |
|
| December 16, 2008 |
REMEDENT, INC. ANNOUNCES RESTRUCTURING OF ITS OTC DIVISION EX-99 10 ex99-1.htm FOR IMMEDIATE RELEASE CONTACT: Stephen Ross Stephen D. Axelrod, CFA (Investors) Director Alisa Steinberg (Media) Remedent, Inc. Wolfe Axelrod Weinberger Assoc. LLC 310-922-5685 212-370-4500 [email protected] [email protected] [email protected] REMEDENT, INC. ANNOUNCES RESTRUCTURING OF ITS OTC DIVISION Deurle, Belgium– December 16, 2008 - Remedent, Inc. (OTCBB:REMI), a |
|
| December 16, 2008 |
EX-17 9 ex17-1.htm RESIGNATION LETTER To: Board of Directors of Remedent, Inc., a Nevada corporation, and Remedent N.V., a Belgium corporation, (collectively, the “Companies”): I hereby tender my resignation as a Director, Chief Executive Officer and any other position(s) that I may hold, or may be construed to hold, with the Companies. I hereby request that you accept this letter of resignation a |
|
| December 16, 2008 |
EX-10 7 ex10-6.htm EXECUTION COPY UNSECURED PROMISSORY NOTE €1,000,160 Nevada December 10,2008 In consideration of the purchase of a ninety-nine shares of Sylphar N.V., a company incorporated and existing under the laws of Belgium, by Remedent, Inc., a Nevada corporation (the “Maker”) from Remedent N.V., a company incorporating and existing under the laws of Belgium and a wholly owned subsidiary o |
|
| December 16, 2008 |
Voting Agreement between Remedent, Inc., and Robin List, dated December 10, 2008 (5) EX-10 8 ex10-7.htm EXECUTION COPY VOTING AGREEMENT THIS VOTING AGREEMENT (the “Agreement”) is made as of this 10th day of December,, 2008, by and among Remedent, Inc., a Nevada corporation (“Remedent”), and Robin List (“List”), Mr. List and Remedent are shareholders of Remedent OTC BV, a company formed under the laws of Belgium (the “Company”). Remedent and Mr. List are referred to collectively he |
|
| November 19, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2008 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 00 |
|
| November 14, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0058 Expires: April 30, 2009 Estimated average burden hours per response . . . . . . . 2.50 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-15975 CUSIP NUMBER (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: September |
|
| November 7, 2008 |
GLAMTECH-USA, INC. FINANCIAL STATEMENTS AUGUST 24, 2008 Exhibit 99.1 GLAMTECH-USA, INC. FINANCIAL STATEMENTS AUGUST 24, 2008 INDEPENDENT AUDITORS? REPORT REPORT OF INDEPENDENT REGISTERED ACCOUNTING FIRM To the Board of Directors and Stockholders of Remedent, Inc.: We have audited the accompanying balance sheet of Glamtech-USA Inc. as of August 24, 2008 and the related statement of operations, and cash flows for the period from April 9, 2008 (inception) |
|
| November 7, 2008 |
e8vkza UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A-1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2008 REMEDENT, INC. (Exact name of registrant as specified in its charter) Nevada 001-15975 86-0837251 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 7, 2008 |
REMEDENT, INC. AND SUBSIDIARIES PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS JUNE 30, 2008 Exhibit 99.2 REMEDENT, INC. AND SUBSIDIARIES PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS JUNE 30, 2008 (unaudited) REMEDENT, INC. AND SUBSIDIARIES PRO FORMA CONDENSED COMBINED BALANCE SHEET (unaudited) Remendent, PRO FORMA Inc. and CONDENSED Subsidiaries GlamTech-USA, Inc. COMBINED June 30 June 30, PRO FORMA BALANCE 2008 2008 ADJUST- SHEET (unaudited) (unaudited) Notes MENTS (unaudited) ASSE |
|
| August 29, 2008 |
Table of Contents Prospectus Supplement No. 3 to Prospectus dated November 5, 2007 Registration No. 333-127193 Filed pursuant to Rule 424(b)(3) PROSPECTUS 5,232,412 Shares REMEDENT, INC. Common Stock Supplement No. 3 To Prospectus Dated November 5, 2007 This Prospectus Supplement No. 3 supplements our Prospectus dated November 5, 2007 and filed with the Securities and Exchange Commission (the “SEC |
|
| August 28, 2008 |
Exhibit 4.1 THE SECURITIES REPRESENTED HEREBY MAY NOT BE TRANSFERRED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT OF 1933, AS AMENDED, (II) SUCH SECURITIES MAY BE SOLD PURSUANT TO RULE 144, OR (III) THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO IT THAT SUCH TRANSFER MAY LAWFULLY BE MADE WITHOUT REGISTRATION UNDER THE SECURITIES |
|
| August 28, 2008 |
e8vk Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 28, 2008 |
Exhibit 10.1 [***] Represents material which has been redacted and filed separately with the Commission pursuant to a request for confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. DISTRIBUTION, LICENSE AND MANUFACTURING AGREEMENT by and among REMEDENT, INC., REMEDENT, N.V., and DEN-MAT HOLDINGS, LLC Dated as of August 24, 2008 TABLE OF CONTENTS Page |
|
| August 28, 2008 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of this 24th day of August, 2008 by and among Remedent, Inc., a Nevada corporation (the ?Company?), and Den-Mat Holdings, LLC (the ?Initial Investor?) pursuant to that certain Distribution, License and Manufacturing Agreement by and among the Company, Remedent, N.V, and Den- |
|
| August 28, 2008 |
Exhibit 10.3 RESCISSION AGREEMENT THIS RESCISSION AGREEMENT (this ?Agreement?) is made as of August 22, 2008, by and among Remedent, Inc., a Nevada corporation (the ?Company?), the Company?s wholly-owned subsidiary Remedent N.V., a Belgium corporation (?Remedent Belgium?), and Glamtech-USA, Inc., a Delaware corporation (?Glamtech?). WHEREAS, Remedent Belgium granted Glamtech the exclusive right to |
|
| August 28, 2008 |
Exhibit 4.2 [***] Represents material which has been redacted and filed separately with the Commission pursuant to a request for confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. STOCK PURCHASE AGREEMENT THIS STOCK PURCHASE AGREEMENT (this ?Agreement?) is made by and between Remedent, Inc., a Nevada corporation (?Remedent?), having a principal place |
|
| August 28, 2008 |
Exhibit 99.1 FOR IMMEDIATE RELEASE CONTACT: For Remedent, Inc. For Den-Mat Holdings, LLC Guy De Vreese, Chairman Mike Beyer, Sam Brown Inc. Remedent, Inc. 773-463-4211 32 9 32170 80 [email protected] [email protected] Stephen D. Axelrod, CFA (Investors) Alisa Steinberg (Media) Wolfe Axelrod Weinberger Associates, LLC 212-370-4500 [email protected] [email protected] REMEDENT, INC. AND DE |
|
| August 27, 2008 |
Table of Contents Prospectus Supplement No. 3 to Prospectus dated October 23, 2007 Registration No. 333-144745 Filed pursuant to Rule 424(b)(3) PROSPECTUS 9,800,000 Shares REMEDENT, INC. Common Stock Supplement No. 3 To Prospectus Dated October 23, 2007 This Prospectus Supplement No. 3 supplements our Prospectus filed October 23, 2007 with the Securities and Exchange Commission (the ?SEC?), and ou |
|
| August 19, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q e10vq Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 14, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0058 Expires: April 30, 2009 Estimated average burden hours per response . . . . . . . 2.50 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-15975 CUSIP NUMBER (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: June 30, 2 |
|
| July 15, 2008 |
Exhibit 21.1 Subsidiaries of Remedent, Inc. ? Remedent Professional Holdings, Inc., a California corporation ? Remedent Professional, Inc., a California corporation (a subsidiary of Remedent Professional Holdings, Inc.) ? Remedent N.V., a Belgium corporation ? Remedent Asia Pte Ltd, a Singapore company ? Sylphar N.V., a Belgium corporation |
|
| July 15, 2008 |
e10ksb Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 7, 2008 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2008 REMEDENT, INC. (Exact name of registrant as specified in its charter) Nevada (State or Other Jurisdiction of Incorporation) 001-15975 (Commission File Number) 86-0837251 |
|
| July 7, 2008 |
SensAble technologie5 OEM Agreement - Confidential This Agreement, effective on the 30th day of June, 2008 (the "Effective Date") is made between SensAble Technologies Inc®, a corporation organized under the laws of the State of Delaware ("Manufacturer" or "SensAble") and Remedent, Inc. |
|
| July 2, 2008 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2008 REMEDENT, INC. (Exact name of registrant as specified in its charter) Nevada 001-15975 86-0837251 (State or Other Jurisdiction of Incorporation) (Co |
|
| July 2, 2008 |
EXHIBIT 10.1 EXCLUSIVE DISTRIBUTION AGREEMENT Certain portions of this exhibit have been omitted based upon request for confidential treatment. The method used to identify the omitted confidential information is: [ *** ] The complete exhibit containing the redacted information has been filed separately with the Commission. This Exclusive Distribution Agreement (the? Agreement?), is made and effect |
|
| July 2, 2008 |
Exhibit 99.1 FOR IMMEDIATE RELEASE CONTACT: Guy De Vreese Stephen D. Axelrod, CFA (Investors) Chairman Alisa Steinberg (Media) Remedent, Inc. Wolfe Axelrod Weinberger Associates, LLC 011-32475470800 212-370-4500 [email protected] [email protected] [email protected] REMEDENT, INC. ANNOUNCES LAUNCH OF EXCLUSIVE STRATEGIC MARKETING PROGRAM WITH GLAMTECH USA, INC. FOR THE DISTRIBUTION OF GLA |
|
| June 27, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0058 Expires: April 30, 2009 Estimated average burden hours per response . . . . . . 2.50 FORM 12b–25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-15975 CUSIP NUMBER 75954T104 (Check one): x Form 10-KSB o Form 20-F o Form 11-K o Form 10-QSB o Form 10-D o Form N-SAR o Form N-CSR For Period Ended |
|
| April 30, 2008 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2008 REMEDENT, INC. (Exact name of registrant as specified in its charter) Nevada (State or Other Jurisdiction of Incorporation) 001-15975 (Commission File Number) 86-083725 |
|
| April 30, 2008 |
EX-10 2 ex10-1.htm FACTORING AGREEMENT DATE: April 24, 2008 SELLER: Remedent, Inc., a Nevada corporation ADDRESS: 4035 East Thousand Oaks Boulevard, Suite 245 West Lake Village, California 91362 FACTOR: FIRST COMMUNITY FINANCIAL, a division of Pacific Western Bank ADDRESS: 4000 North Central Avenue, Suite 100 Phoenix, AZ 85012 1. PURPOSE OF AGREEMENT. This Agreement sets forth the terms and condit |
|
| April 30, 2008 |
FIRST COMMUNITY FINANCIAL VALIDITY AGREEMENT EX-10 4 ex10-2.htm FIRST COMMUNITY FINANCIAL VALIDITY AGREEMENT To induce First Community Financial, a division of Pacific Western Bank (“Factor”) to enter into that certain Factoring Agreement dated April 24, 2008, as amended from time to time, (the “Factoring Agreement”) with Remedent, Inc., a Nevada corporation (“Assignor”), and in consideration of any and all loans, advances, and/or financial |
|
| April 15, 2008 |
EX-10.1 2 f39868exv10w1.htm EXHIBIT 10.1 EXHIBIT 10.1 EXCLUSIVE DISTRIBUTION AGREEMENT Certain portions of this exhibit have been omitted based upon request for confidential treatment. The method used to identify the omitted confidential information is: [ *** ] The complete exhibit containing the redacted information has been filed separately with the Commission. This Exclusive Distribution Agreem |
|
| April 15, 2008 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2008 REMEDENT, INC. (Exact name of registrant as specified in its charter) Nevada 001-15975 86-0837251 (State or Other Jurisdiction of Incorporation) (Comm |
|
| April 15, 2008 |
Exhibit 99.1 FOR IMMEDIATE RELEASE CONTACT: Guy De Vreese Stephen D. Axelrod, CFA (Investors) Chairman Alisa Steinberg (Media) Remedent, Inc. Wolfe Axelrod Weinberger Associates, LLC 011-32475470800 212-370-4500 [email protected] [email protected] [email protected] REMEDENT, INC. ANNOUNCES LAUNCH OF EXCLUSIVE STRATEGIC MARKETING PROGRAM WITH GLAMTECH USA, INC. FOR THE DISTRIBUTION OF GLA |
|
| April 14, 2008 |
Table of Contents Prospectus Supplement No. 2 to Prospectus dated October 23, 2007 Registration No. 333-144745 Filed pursuant to Rule 424(b)(3) PROSPECTUS 9,800,000 Shares REMEDENT, INC. Common Stock Supplement No. 2 To Prospectus Dated October 23, 2007 This Prospectus Supplement No. 2 supplements our Prospectus dated and filed October 23, 2007 with the Securities and Exchange Commission, and our |
|
| April 14, 2008 |
Table of Contents Prospectus Supplement No. 2 to Prospectus dated November 5, 2007 Registration No. 333-127193 Filed pursuant to Rule 424(b)(3) PROSPECTUS 5,420,022 Shares REMEDENT, INC. Common Stock Supplement No. 2 To Prospectus Dated November 5, 2007 This Prospectus Supplement No. 2 supplements our Prospectus dated November 5, 2007 and filed with the Securities and Exchange Commission on Novemb |
|
| February 14, 2008 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB þ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2007 or o TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-15975 REMEDENT, INC. (Exact name of small business |
|
| February 13, 2008 |
OMB APPROVAL OMB Number: 3235-0145 Expires: January 31, 2008 Estimated average burden hours per response. |
|
| December 19, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2007 REMEDENT, INC. (Exact name of registrant as specified in its charter) Nevada (State or Other Jurisdiction of Incorporation) 001-15975 (Commission File Number) 86-083 |
|
| December 19, 2007 |
REMEDENT, INC. ANNOUNCES EXCLUSIVE DISTRIBUTION AGREEMENT WITH LEADING OTC DISTRITUBOR ENCOMPASSING THE NETHERLANDS DEURLE, Belgium?December 14, 2007 - Remedent, Inc. (OTCBB: REMI) today announced that it has signed an exclusive distribution agreement with a leading OTC distributor in the Netherlands. The terms call for this distributor to sell a private label kit similar to Reme)sense?, to treat |
|
| December 19, 2007 |
EXHIBIT 10.1 Certain portions of this exhibit have been omitted based upon request for confidential treatment. The method used to identify the omitted confidential information is: [***] The complete exhibit containing the redacted information has been filed separately with the Commission. REMEDENT global dental solutions THIS AGREEMENT is made on November 26th, 2007 BETWEEN (1) REMEDENT NV, a corp |
|
| December 11, 2007 |
Table of Contents Prospectus Supplement No. 1 to Prospectus dated October 23, 2007 Registration No. 333-144745 Filed pursuant to Rule 424(b)(3) PROSPECTUS 9,800,000 Shares REMEDENT, INC. Common Stock Supplement No. 1 To Prospectus Dated October 23, 2007 This Prospectus Supplement supplements our Prospectus dated October 23, 2007 filed with the Securities and Exchange Commission on October 23, 2007 |
|
| December 11, 2007 |
Table of Contents Prospectus Supplement No. 1 to Prospectus dated November 5, 2007 Registration No. 333-127193 Filed pursuant to Rule 424(b)(3) PROSPECTUS 5,420,022 Shares REMEDENT, INC. Common Stock Supplement No. 1 To Prospectus Dated November 5, 2007 This Prospectus Supplement supplements our Prospectus dated November 5, 2007 and filed with the Securities and Exchange Commission on November 6, |
|
| November 26, 2007 |
EX-10.1 2 f35828a1exv10w1.htm EXHIBIT 10.1 Exhibit 10.1 Limited Liability Company Merger and Equity Reallocation Agreement This Limited Liability Company Equity Reallocation Agreement (“Agreement”) is entered into as of July 15, 2007 among those members and officers as listed in Exhibit A. In consideration of the mutual promises made and for other good and valuable consideration, the parties agree |
|
| November 26, 2007 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB AMENDMENT NO. 1 þ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2007 or o TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-15975 REMEDENT, INC. (Exact name |
|
| November 19, 2007 |
e10qsb Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| November 19, 2007 |
Exhibit 10.1 Limited Liability Company Merger and Equity Reallocation Agreement This Limited Liability Company Equity Reallocation Agreement (“Agreement”) is entered into as of July 15, 2007 among those members and officers as listed in Exhibit A. In consideration of the mutual promises made and for other good and valuable consideration, the parties agree as follows: 1. Definitions For purposes of |
|
| November 13, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0058 Expires: April 30, 2009 Estimated average burden hours per response . . . . . . 2.50 FORM 12b–25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-15975 CUSIP NUMBER 75954T104 (Check one): o Form 10-KSB o Form 20-F o Form 11-K x Form 10-QSB o Form 10-D o Form N-SAR o Form N-CSR For Period Ended |
|
| November 6, 2007 |
PROSPECTUS 5,420,022 Shares REMEDENT, INC. Common Stock Table of Contents Filed Pursuant Rule 424(b)(3) Registration No. 333-127193 PROSPECTUS 5,420,022 Shares REMEDENT, INC. Common Stock This Prospectus relates to the sale or other disposition of 5,420,022 shares of common stock, $.001 par value, by the Selling Stockholders listed under ?Selling Stockholders? on page 35 or their transferees. This Prospectus also covers the sale or other disposition of |
|
| November 1, 2007 |
As filed with the Securities and Exchange Commission on October 31, 2007 posam Table of Contents As filed with the Securities and Exchange Commission on October 31, 2007 Registration No. |
|
| October 23, 2007 |
corresp Scott E. Bartel Direct Dial: (916) 930-2513 E-mail: [email protected] October 23, 2007 Russell Mancuso, Branch Chief U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE, Mail Stop 6010 Washington, DC 20549-7010 Re: Remedent, Inc. Registration Statement on Form SB-2 Filed July 20, 2007, Amended September 14, 2007 and October 19, 2007 File No. 33 |
|
| October 23, 2007 |
As filed with the Securities and Exchange Commission on October 23, 2007 sbv2za Table of Contents As filed with the Securities and Exchange Commission on October 23, 2007 Registration No. |
|
| October 23, 2007 |
Exhibit 10.37 THIS AGREEMENT is made on 1st October, 2007 BETWEEN (1) REMEDENT NV, a corporation under the laws of Belgium, whose registered office is at 9831 Deurle, Xavier De Cocklaan 42, Belgium (“Remedent”); hereby represented by Mr Robin List, Managing Director; AND (2) Savant Distribution Limited, a limited company incorporated under the laws of England and Wales whose registered company num |
|
| October 23, 2007 |
PROSPECTUS 9,800,000 Shares REMEDENT, INC. Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-144745 PROSPECTUS 9,800,000 Shares REMEDENT, INC. Common Stock This Prospectus relates to the sale or other disposition of 5,600,000 shares of common stock, $.001 par value, by the Selling Stockholders listed under “Selling Stockholders” on page 39 or their transferees. This Prospectus also covers the sale or other disposition |
|
| October 19, 2007 |
Exhibit 99.9 DECLARATION I, Jon D Gruber , do declare and state as follows: (Print Name of Declarant) I have personal knowledge of the facts stated herein and if called upon to testify thereto, I could and would do so competently. On or about June 25, 2007, Jon D. and Linda W. Gruber Trust (the ?Investor?) acquired shares of common stock (the ?Shares?) and common stock purchase warrants (the ?Warr |
|
| October 19, 2007 |
Exhibit 99.5 DECLARATION I, Austin W. Marxe , do declare and state as follows: (Print Name of Declarant) I have personal knowledge of the facts stated herein and if called upon to testify thereto, I could and would do so competently. On or about June 25, 2007, Special Situations Cayman Fund LP (the ?Investor?) acquired shares of common stock (the ?Shares?) and common stock purchase warrants (the ? |
|
| October 19, 2007 |
Exhibit 99.4 DECLARATION I, Austin W. Marxe , do declare and state as follows: (Print Name of Declarant) I have personal knowledge of the facts stated herein and if called upon to testify thereto, I could and would do so competently. On or about June 25, 2007, Special Situations Private Equity Fund L.P. (the ?Investor?) acquired shares of common stock (the ?Shares?) and common stock purchase warra |
|
| October 19, 2007 |
EX-99.2 6 f31776a2exv99w2.htm EXHIBIT 99.2 Exhibit 99.2 DECLARATION I, Ian P. Ellis , do declare and state as follows: (Print Name of Declarant) I have personal knowledge of the facts stated herein and if called upon to testify thereto, I could and would do so competently. On or about June 25, 2007, MicroCapital Fund LP (the “Investor”) acquired shares of common stock (the “Shares”) and common sto |
|
| October 19, 2007 |
Exhibit 99.10 DECLARATION I, Paul H. O?Leary , do declare and state as follows: (Print Name of Declarant) I have personal knowledge of the facts stated herein and if called upon to testify thereto, I could and would do so competently. On or about June 25, 2007, Raffles Associates, LP (the ?Investor?) acquired shares of common stock (the ?Shares?) and common stock purchase warrants (the ?Warrants?) |
|
| October 19, 2007 |
Exhibit 99.12 DECLARATION I, Paul J. Solit , do declare and state as follows: (Print Name of Declarant) I have personal knowledge of the facts stated herein and if called upon to testify thereto, I could and would do so competently. On or about June 25, 2007, Potomac Capital Partners LP (the ?Investor?) acquired shares of common stock (the ?Shares?) and common stock purchase warrants (the ?Warrant |
|
| October 19, 2007 |
EX-99.7 11 f31776a2exv99w7.htm EXHIBIT 99.7 Exhibit 99.7 DECLARATION I, J. Patterson McBaine , do declare and state as follows: (Print Name of Declarant) I have personal knowledge of the facts stated herein and if called upon to testify thereto, I could and would do so competently. On or about June 25, 2007, Gruber & McBaine International (the “Investor”) acquired shares of common stock (the “Shar |
|
| October 19, 2007 |
Exhibit 99.11 DECLARATION I, J. Patterson McBaine , do declare and state as follows: (Print Name of Declarant) I have personal knowledge of the facts stated herein and if called upon to testify thereto, I could and would do so competently. On or about June 25, 2007, Lagunitas Partners LP (the ?Investor?) acquired shares of common stock (the ?Shares?) and common stock purchase warrants (the ?Warran |
|
| October 19, 2007 |
Exhibit 99.8 DECLARATION I, J. Patterson McBaine, do declare and state as follows: I have personal knowledge of the facts stated herein and if called upon to testify thereto, I could and would do so competently. On or about June 25, 2007, J. Patterson McBaine (the ?Investor?) acquired shares of common stock (the ?Shares?) and common stock purchase warrants (the ?Warrants?) of Remedent, Inc., a Nev |
|
| October 19, 2007 |
CORRESP 22 filename22.htm Scott E. Bartel Direct Dial: (916) 930-2513 E-mail: [email protected] October 19, 2007 Russell Mancuso, Branch Chief U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE, Mail Stop 6010 Washington, DC 20549-7010 Re: Remedent, Inc. Registration Statement on Form SB-2 Filed July 20, 2007, Amended September 14, 2007 File No. 333-1 |
|
| October 19, 2007 |
EX-99.1 5 f31776a2exv99w1.htm EXHIBIT 99.1 Exhibit 99.1 DECLARATION I, Ian P. Ellis , do declare and state as follows: (Print Name of Declarant) I have personal knowledge of the facts stated herein and if called upon to testify thereto, I could and would do so competently. On or about June 25, 2007, MicroCapital Fund Ltd. (the “Investor”) acquired shares of common stock (the “Shares”) and common s |
|
| October 19, 2007 |
As filed with the Securities and Exchange Commission on October 19, 2007 Table of Contents As filed with the Securities and Exchange Commission on October 19, 2007 Registration No. |
|
| October 19, 2007 |
Exhibit 99.6 DECLARATION I, Austin W. Marxe , do declare and state as follows: (Print Name of Declarant) I have personal knowledge of the facts stated herein and if called upon to testify thereto, I could and would do so competently. On or about June 25, 2007, Special Situations Fund III QP LP (the ?Investor?) acquired shares of common stock (the ?Shares?) and common stock purchase warrants (the ? |
|
| October 19, 2007 |
Exhibit 99.14 DECLARATION I, Paul J. Solit , do declare and state as follows: (Print Name of Declarant) I have personal knowledge of the facts stated herein and if called upon to testify thereto, I could and would do so competently. On or about June 25, 2007, Pleiades Investment Partners-R LP (the ?Investor?) acquired shares of common stock (the ?Shares?) and common stock purchase warrants (the ?W |
|
| October 19, 2007 |
Exhibit 99.3 DECLARATION I, Neal I. Goldman, do declare and state as follows: I have personal knowledge of the facts stated herein and if called upon to testify thereto, I could and would do so competently. On or about June 25, 2007, Neal I. Goldman (the “Investor”) acquired shares of common stock (the “Shares”) and common stock purchase warrants (the “Warrants”) of Remedent, Inc., a Nevada corpor |
|
| October 19, 2007 |
REMEDENT, INC. Xavier de Cocklaan 42, B-9831 Deurle, Belgium 011-32-9-321-70-80 REMEDENT, INC. Xavier de Cocklaan 42, B-9831 Deurle, Belgium 011-32-9-321-70-80 October 19, 2007 VIA EDGAR AND FACSIMILE (202) 772-9366 Mr. Russell Mancuso Securities and Exchange Commission Mail Stop 6010 100 F Street, N.E. Washington, D.C. 20549 Re: REMEDENT, INC. Registration Statement on Pre-Effective Amendment No. 2 to Form SB-2 File No. 333-144745 Dear Commissioners: Remedent, Inc. (the “Com |
|
| October 19, 2007 |
Exhibit 10.38 WAIVER AGREEMENT WAIVER AGREEMENT (this “Agreement”) is made as of the 18th day of October 2007, by and among Remedent, Inc., a Nevada corporation (the “Company”), and the holders set forth on the signature pages affixed hereto (each a “Consenting Holder” and, collectively, the “Consenting Holders”). Recitals A. The Company, the Consenting Holders and certain other investors (the “Ot |
|
| October 19, 2007 |
Exhibit 10.37 Certain portions of this exhibit have been omitted based upon request for confidential treatment. The method used to identify the omitted confidential information is: [THIS INFORMATION HAS BEEN REDACTED]. The complete exhibit containing the redacted information has been filed separately with the Commission. THIS AGREEMENT is made on 1st October, 2007 BETWEEN (1) REMEDENT NV, a corpor |
|
| October 19, 2007 |
EX-99.13 17 f31776a2exv99w13.htm EXHIBIT 99.13 Exhibit 99.13 DECLARATION I, Paul J. Solit , do declare and state as follows: (Print Name of Declarant) I have personal knowledge of the facts stated herein and if called upon to testify thereto, I could and would do so competently. On or about June 25, 2007, Potomac Capital International Ltd. (the “Investor”) acquired shares of common stock (the “Sha |
|
| October 9, 2007 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.1) Filed by the Registrant þ Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitte |
|
| October 2, 2007 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| September 14, 2007 |
As filed with the Securities and Exchange Commission on September 14, 2007 Table of Contents As filed with the Securities and Exchange Commission on September 14, 2007 Registration No. |
|
| September 14, 2007 |
corresp [Bullivant, Houser, Bailey Letterhead] September 14, 2007 Via EDGAR and Federal Express Mr. |
|
| August 20, 2007 |
e10qsb Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| August 15, 2007 |
REMEDENT, INC. ANNOUNCES APPOINTMENT OF ROGER LEDDINGTON AS HEAD OF U.S. MARKETING EX-99 4 ex99-1.htm FOR IMMEDIATE RELEASE Stephen D. Axelrod, CFA (Investors) Alisa Steinberg (Media) Wolfe Axelrod Weinberger Associates, LLC 212-370-4500 [email protected] [email protected] REMEDENT, INC. ANNOUNCES APPOINTMENT OF ROGER LEDDINGTON AS HEAD OF U.S. MARKETING Deurle, Belgium – August 15, 2007 - Remedent, Inc. (REMI.OB), today announced that it has appointed Roger Leddington |
|
| August 15, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2007 REMEDENT, INC. (Exact name of registrant as specified in its charter) Nevada (State or Other Jurisdiction of Incorporation) 001-15975 (Commission File Number) 86-08372 |
|
| August 15, 2007 |
EX-10 2 ex10-1.htm August 8, 2007 Mr. Roger Leddington 774 Mays Blvd. #10-540 Incline Village, NV 89451 USA Dear Roger, I am pleased to extend this opportunity to join Remedent, Inc. (the “Company”) as Vice-President reporting to the Company’s C.E.O. and/or Chairman. I will review the job description with you under separate cover. We are looking forward to you joining our team, and believe this wi |
|
| August 14, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0058 Expires: April 30, 2009 Estimated average burden hours per response . . . . . . 2.50 FORM 12b–25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-15975 CUSIP NUMBER 75954T104 (Check one): o Form 10-KSB o Form 20-F o Form 11-K x Form 10-QSB o Form 10-D o Form N-SAR o Form N-CSR For Period Ended |
|
| July 30, 2007 |
SEC 1745 (02-02) Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
